STOCKHOLM, April 19th, 2018 /PRNewswire/ --
Moberg Pharma AB (OMX: MOB) announces that Kjell Rensfeldt, VP Research and Development,
will retire in the fall but remain with the company part-time as
Senior Adviser.
On October 1st 2018, Kjell Rensfeldt, VP Research and Development,
will retire from Moberg Pharma, but remain with the company in a
part-time role as Senior Adviser. The process of finding his
replacement has started.
"With extensive knowledge and experience, Kjell has
contributed to the evolution of Moberg Pharma, especially through
the development of Kerasal Nail® and MOB-015, where he has been
instrumental. I've had the pleasure of working with Kjell since
2007 and I am highly grateful for his efforts over the years. I
look forward to continuing our collaboration in his role as Senior
Advisor to the company", says Peter
Wolpert, CEO Moberg
Pharma.
About this information
This information is
information that Moberg Pharma AB is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was
submitted for publication, through the agency of the contact person
set out above, at 9.30 a.m. CET on
April 19th, 2018.
For additional information, please contact:
Peter Wolpert, CEO,
telephone: +1 908 432 22 03 (US), +46 70 735 71 35, e-mail:
peter.wolpert@mobergpharma.se
Anna Ljung, CFO, telephone:
+46 707 66 60 30, e-mail:
anna.ljung@mobergpharma.se
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/moberg-pharma/r/management-change-in-moberg-pharma,c2498924
The following files are available for download:
http://mb.cision.com/Main/1662/2498924/824486.pdf
|
Management change in
Moberg Pharma
|
View original
content:http://www.prnewswire.com/news-releases/management-change-in-moberg-pharma-300632841.html
SOURCE Moberg Pharma